Sunesis Pharmaceuticals (SNSS) Given a $3.00 Price Target by Cantor Fitzgerald Analysts

Sunesis Pharmaceuticals (NASDAQ:SNSS) has been assigned a $3.00 price target by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 11.11% from the company’s current price.

SNSS has been the topic of several other research reports. Zacks Investment Research upgraded Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a report on Thursday, August 24th. UBS began coverage on Sunesis Pharmaceuticals in a report on Monday, November 20th. They set an “outperform” rating on the stock. Oppenheimer began coverage on Sunesis Pharmaceuticals in a report on Tuesday, November 21st. They set an “outperform” rating and a $7.00 price target on the stock. Cowen restated a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Thursday, November 2nd. Finally, Wells Fargo & Company downgraded Sunesis Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $2.70 to $2.00 in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $3.63.

Shares of Sunesis Pharmaceuticals (SNSS) traded down $0.14 during midday trading on Tuesday, reaching $2.70. The company’s stock had a trading volume of 70,300 shares, compared to its average volume of 120,266. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34. Sunesis Pharmaceuticals has a 12 month low of $1.82 and a 12 month high of $4.45.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06). During the same period in the prior year, the firm posted ($0.62) earnings per share. research analysts expect that Sunesis Pharmaceuticals will post -1.58 earnings per share for the current fiscal year.

In other Sunesis Pharmaceuticals news, Director Dayton Misfeldt acquired 400,000 shares of the company’s stock in a transaction dated Friday, October 27th. The shares were acquired at an average price of $2.00 per share, for a total transaction of $800,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Mpm Oncology Impact Management acquired 81,500 shares of the company’s stock in a transaction dated Monday, November 6th. The stock was acquired at an average price of $2.77 per share, for a total transaction of $225,755.00. The disclosure for this purchase can be found here. In the last quarter, insiders bought 506,800 shares of company stock worth $1,091,282. Company insiders own 10.21% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its holdings in shares of Sunesis Pharmaceuticals by 1.1% in the 1st quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after acquiring an additional 1,230 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 18,254 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after acquiring an additional 23,819 shares during the last quarter. Sphera Funds Management LTD. increased its holdings in shares of Sunesis Pharmaceuticals by 54.6% in the 2nd quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 68,212 shares during the last quarter. Finally, Virtu KCG Holdings LLC purchased a new position in shares of Sunesis Pharmaceuticals in the 2nd quarter valued at about $208,000. Institutional investors and hedge funds own 38.43% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/05/sunesis-pharmaceuticals-snss-given-a-3-00-price-target-by-cantor-fitzgerald-analysts.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

What are top analysts saying about Sunesis Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sunesis Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit